Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 10/20 | 0.37 |
| ▸ | EED | O75530 | 9/20 | 0.37 |
| ▸ | RBBP4 | Q09028 | 9/20 | 0.37 |
| ▸ | SUZ12 | Q15022 | 9/20 | 0.37 |
| ▸ | AEBP2 | Q6ZN18 | 9/20 | 0.37 |
| ▸ | SPR | P35270 | 6/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21113320 | 0.90 | EZH2 (0.38) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL21113154 | 0.84 | EZH2 (0.35) | EZH2 | |
| SCHEMBL22872284 | 0.83 | EZH2 (0.34) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL19964603 | 0.81 | EED (0.53) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL21342282 | 0.81 | EZH2 (0.63) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL28886501 | 0.74 | OPRK1 (0.31) | EZH2 | |
| SCHEMBL21342365 | 0.74 | RORC (0.30) | RORC | |
| SCHEMBL21156606 | 0.73 | EZH2 (0.34) | EZH2 | |
| SCHEMBL29986791 | 0.73 | EZH2 (0.34) | EZH2 | |
| SCHEMBL21113520 | 0.72 | EZH2 (0.49) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661421-B2 | Indolizine compounds, preparation method and use thereof | HAIHE BIOPHARMA CO., LTD. (CN) | 2023-05-30 | — | — | US | disclosed |
| US-11661421-B2 | Indolizine compounds, preparation method and use thereof | HAIHE BIOPHARMA CO., LTD. (CN) | 2023-05-30 | — | — | US | disclosed |
| CN-110229151-B | Indolizine compound, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-20200399270-A1 | INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2020-12-24 | — | — | US | disclosed |
| US-20200399270-A1 | INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661421-B2 | Indolizine compounds, preparation method and use thereof | EZH1, EZH2, IKZF3 | EZH2 2/4885EED 12/4885RBBP4 1315/4885 |
| US-20200399270-A1 | INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | EZH1, EZH2, IKZF3 | EZH2 2/4885EED 12/4885RBBP4 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.